California is currently home to 5615 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Recruiting
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. A substudy will enroll participants from Arms A and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: City of Hope, Duarte, California
Conditions: Carcinoma, Non-Small-Cell Lung
Age-dependent Effects of Smoked and Oral Delta-9-THC
Recruiting
This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/28/2025
Locations: UCLA Center for Cannabis and Cannabinoids, Los Angeles, California
Conditions: Pain, Abuse, Drug, Intoxication; Cannabinoids
Cold Agglutinin Disease Real World Evidence Registry
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 \[NCT02502903,CAD patients\], BIVV009-03/EFC16215 \[NCT03... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: SLO Oncology and Hematology Site Number : 1235, San Luis Obispo, California
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
Recruiting
A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: UCSF Benioff Children's Hospital Oakland, Oakland, California
Conditions: Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
Two-fraction HDR Monotherapy for Localized Prostate Cancer
Recruiting
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fractions on separate days, or at least 6 hours apart. Clinically, this regimen, if shown to be safe and effective in future studies, has the potential to reduce operative resources and logistical stresses... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma
Device Global Registry for the IlluminOss Bone Stabilization System
Recruiting
This is a multi-center, observational patient registry. The primary objective of the study is to collect safety and performance data on the IlluminOss Device when used to provide stabilization and alignment for the treatment of traumatic or impending and pathologic fractures.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/28/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Traumatic Fracture, Pathological Fracture
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Recruiting
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity m... Read More
Gender:
ALL
Ages:
Between 10 years and 30 years
Trial Updated:
04/28/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Lymphoblastic Leukemia, Myeloid Leukemia
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Recruiting
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research questions, including: * Side effects that may be experienced from taking vonsetamig * How vonsetamig works in the body * How much vonsetamig is present in the blood * If vonsetamig works to... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/28/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Chronic Kidney Disease (CKD)
Study of SGN1 in Patients With Advanced Solid Tumor
Recruiting
Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Rationale:The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-M... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2025
Locations: Health Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Advanced Solid Tumor
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Recruiting
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Shiley Center for Orthopaedic Research and Education at Scripps Clinic, La Jolla, California
Conditions: Adult Spinal Deformity, Scoliosis, Kyphosis
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
Recruiting
The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: UCSD Medical Center Hillcrest, La Jolla, California
Conditions: Aortic Aneurysm, Abdominal
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Fresno, California
Conditions: Generalized Myasthenia Gravis